

**JAGADISHWAR**

**PHARMACEUTICAL  
WORKS LIMITED**

CIN : L24232AS1987PLC002803

205, HARIBOL ROY MARKET, 2<sup>nd</sup> FLOOR, A.T.ROAD, GUWAHATI-781001

Website: jagadishwarpharma.com

E\_mail ID : jpwLtd@yahoo.com

Phone no.: 1917890587489

Date: May 17, 2016

To  
Compliance Department  
Metropolitan Stock Exchange of India Limited  
4<sup>th</sup> Floor, Vibgyor Towers, Plot No. C 62,  
G Block, Opp. Trident Hotel,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 098

**Sub: Submission of Quarterly audited financial results under regulation 33(3)(a) for the quarter ended March 31, 2016**

Dear Sir/Madam,

Please find enclosed herewith the Quarterly audited financial results along with limited review report under regulation 33(3)(a) of SEBI(LODR), 2015 for the quarter ended 31<sup>st</sup> March, 2016.

Request to update your records.

Thanking You.

For Jagadishwar Pharmaceutical Works Limited

  
Swapan Sarker  
Executive Director  
DIN: 05149442

Encl: As above

**Jagadishwar Pharmaceutical Works Limited**  
**Regd. Office : 205, Haribol Roy Market, A.T.Road**  
**2nd Floor, Near Saraf Building, Guwahati - 781 001**

**Statement of Standalone Audited Financial Results (Provisional) of Quarter Ended On 31st March, 2016**

(Rs. In Lakhs)

	Particulars	Quarter Ended 31/03/2016	Quarter Ended 31/12/2015	Quarter Ended 31/03/2015	Year Ended 31/03/2016	Year Ended 31/03/2015
	(Refer Notes Below)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income from Operations</b>					
	(a) Net sales/income from operation (Net of excise duty)	41.28	435.00	24.00	484.66	81.72
	(b) Other operating income	-	-	-	-	-
	<b>Total income from operations (net)</b>	<b>41.28</b>	<b>435.00</b>	<b>24.00</b>	<b>484.66</b>	<b>81.72</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchase of stock-in-trade	24.50	4.50	8.00	130.00	37.92
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	16.78	460.50	40.00	390.66	91.30
	(d) Employee benefits expense	2.02	2.01	1.97	8.00	6.44
	(e) Depreciation and amortisation expense	1.57	-	1.58	1.57	1.58
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	3.26	1.51	1.87	7.26	13.63
	<b>Total expenses</b>	<b>48.13</b>	<b>468.52</b>	<b>53.42</b>	<b>537.49</b>	<b>150.87</b>
3	<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>(6.85)</b>	<b>(33.52)</b>	<b>(29.42)</b>	<b>(52.83)</b>	<b>(69.15)</b>
4	Other income	11.22	11.34	18.65	58.44	74.76
5	<b>Profit/ (Loss) from ordinary activities before finance costs and exceptional (3(+ /-)4)</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
6	Finance costs	-	-	-	-	-
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5(+/-)6)</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
8	Exceptional items	-	-	-	-	-
9	<b>Profit / (Loss) from ordinary activities before tax (7(+/-)8)</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
10	Tax expense	-	-	-	-	-
11	<b>Net Profit / (Loss) from ordinary activities after tax (9(+/-)10)</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
12	Extraordinary items (net of expense Rs. ____ Lakhs)	-	-	-	-	-
13	<b>Net Profit / (Loss) for the period (11(+/-)12)</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
14	Share of profit / (Loss) of associates*	-	-	-	-	-
15	Minority interest*	-	-	-	-	-
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / loss of associates (13(+/-)14(+/-)15)*</b>	<b>4.37</b>	<b>(22.18)</b>	<b>(10.77)</b>	<b>5.61</b>	<b>5.61</b>
17	Paid-up equity share capital (Face Value of Share is Rs.10/- each)	2,970.02	2,970.02	2,970.02	2,970.02	2,970.02
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	10.36
19 i	<b>Earnings per share (before extraordinary items)</b> (of Rs. ____/- each ) (not annualised):					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
19 ii	<b>Earnings per share (after extraordinary items)</b> (of Rs. ____/- each ) (not annualised):					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-

see accompanying note to the financial results

\* Applicable in the case of consolidated results

Note:

Profit / loss from discontinuing operations, if any, included in the above shall be disclosed separately with details thereof.

A company which presents quarterly financial results in accordance with Ind AS 34 Interim Financial Reporting (applicable under Companies (Indian Accounting Standards) Rules, 2015) for the period covered by its first Ind AS financial statement shall comply with the requirements of paragraph 32 of Ind AS 101 - First time

Place : Guwahati  
Date : 17.05.2016

*Jagadishwar Pharmaceutical Works Limited*  
*Guwahati*  
*17.05.2016*

Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

	Stadalone / Consolidated Statement of Assets and Liabilities Particulars	As at (current half year end) (31/03/2016)	As at (Previous year end) (31/03/2015)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholder's funds</b>		
	(a) Share capital	2,970.02	2,970.02
	(b) Reserves and surplus	15.97	10.36
	© Money received against share warrants		
	<b>Sub- total - Shareholder's funds</b>	<b>2,985.99</b>	<b>2,980.38</b>
	<b>Share application money pending allotment</b>	-	-
2			
3	<b>Minority interest*</b>	-	-
4	<b>Non-current liabilities</b>		
	(a) Long-term borrowings	-	-
	(b) Deferred tax liabilities (net)	-	-
	© Other long-term liabilities	-	-
	(d) Long-term provisions	-	-
	<b>Sub-total-Non-current liabilities</b>	-	-
5	<b>Current liabilities</b>		
	(a) Short-term borrowings	-	-
	(b) Trade payables	-	-
	(c ) Other current liabilities	-	-
	(d) Short-term provisions	0.15	0.10
	<b>Sub-total- Current liabilities</b>	<b>0.15</b>	<b>0.10</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,986.14</b>	<b>2,980.48</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Fixed assets	2.97	4.54
	(b) Goodwill on consolidation*	-	-
	(c ) Non-current investments	1,659.61	1,068.12
	(d) Deferred tax assets (net)	-	-
	(e) Long-term loans and advances	17.16	11.31
	(f) Other non-current assets	-	-
	<b>Sub-total-Non-current assets</b>	<b>1,679.74</b>	<b>1,083.97</b>
2	<b>Current assets</b>		
	(a) Current investments	-	-
	(b) Inventories	833.44	1,224.10
	© Trade receivables	-	-
	(d) Cash and cash equivalents	1.47	1.73
	(e) Short-term loans and advances	471.49	670.68
	(f) Other current assets	-	-
	<b>Sub-total-Current assets</b>	<b>1,306.40</b>	<b>1,896.51</b>
	<b>TOTAL - ASSETS</b>	<b>2,986.14</b>	<b>2,980.48</b>

\* Applicable in the case of consolidated statement of assets and liabilities.

Swastha Pharmaceutical Works  
Gowabadi  
Sachin Saket  
Mumbai